Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
IDYA
vs
S&P 500
IDYA
S&P 500
Over the past 12 months, IDYA has outperformed S&P 500, delivering a return of +38% compared to S&P 500's +19% growth.
Stocks Performance
IDYA vs S&P 500
Performance Gap
IDYA vs S&P 500
Performance By Year
IDYA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
IDEAYA Biosciences Inc
Glance View
IDEAYA Biosciences is a biotechnology company that develops cancer drugs aimed at tumors with specific genetic weaknesses. Its work focuses on precision oncology, especially small-molecule medicines designed to block the pathways cancer cells depend on while sparing healthier cells. The company’s main assets are its drug candidates and the science behind matching the right drug to the right tumor type. IDEAYA does not sell consumer products. It makes money mainly through collaboration deals with larger pharmaceutical companies, plus licensing payments, research funding, milestone payments, and potential royalties if partnered drugs succeed. If its own programs reach the market, it could also earn direct drug sales revenue, but today it is primarily a drug developer rather than a commercial seller. What makes IDEAYA’s business different is its focus on synthetic lethality and other biomarker-driven cancer targets. Instead of trying to treat all cancers the same way, it builds medicines for patients whose tumors carry certain mutations or vulnerabilities. That places the company in the high-risk, high-reward part of biotech, where scientific validation and partner relationships are central to the business model.